Redeye comments on Genovis’ decision to acquire the remaining 75% of SEQURNA, viewing it as a logical, synergistic move that leverages its g...
Redeye updates its outlook on Genovis following a Q1 report coming in slightly above our estimates across the board.
Redeye shares its initial take on Genovis following the Q1 report, which delivered sales 13% above our estimates and an EBITDA margin of 28%...
Redeye updates its view on Genovis following the company's year-end report.
Redeye's provides its initial take on Genovis' year-end report which came in softer than we had estimated, albeit still showing strong growt...
Redeye provides an updated view on Genovis following a Q3 report that surpassed our estimates across the board.
Redeye provides its initial take on Genovis' Q3 report, which exceeded expectations across the board.
Redeye leaves a brief comment on today's news that Genovis' has launched the second generation of its FabRICATOR enzyme while also reiterati...
Redeye updates its view on Genovis following the Q2 report and the announced divestment of its antibody business.
Redeye sees the Q2 report coming in below estimates for both sales and EBIT.
Redeye comments on Genovis following the announcement of a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors.
Redeye sees a Q1 report from Genovis largely aligning with our estimates with minor deviation on the downside for sales and upside for EBIT.
Redeye gives its view on yesterday's press release from Genovis' which stated that the deal between Carthesian Therapeutics and Genovis has ...
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest Analyst Q&A.
Redeye adjusts its estimates and fair value range following Genovis’ year-end report, which came in below our estimates but suggests a stron...
Redeye see a softer than anticipated Q4 report from Genovis which came in below expectations on both sales and EBIT on account of sluggish c...
Redeye adjusts its estimates and share its preview of Genovis’ Q4 2023 report due on February 15th.
Redeye updates its view on Genovis following its Q3 2023 report and the announced merger between Selecta and Cartesian Therapeutics.
Redeye see a Q3 report from Genovis that came in just above our estimates in terms of sales but delivered a solid beat on the EBIT level.
Redeye continues to see potential for stellar growth ahead for Genovis following its Q2 2023 report, which showcased 40% sales growth couple...
Redeye remains positive on Genovis following a Q2 that showcased 40% sales growth in the analytics business, alongside EBIT margins of 20%.
Redeye slightly ups its forecasts and valuation on the back of a strong Q1 2023 report, which marked the strongest performance to date in te...
Redeye comments on Genovis Q1 2023, which delivered a beat on practically all metrics on the back of the milestone from Selecta/Astellas.
Redeye looks positively upon today’s news that Genovis has teamed with ArcticZymes Technologies to benefit from synergies facilitating the g...
Redeye looks positively upon today’s announcement that Genovis has acquired the patent rights to a unique DNA polymerase with potential appl...
Redeye returns with an updated take on the pick-and-shovel play Genovis following its partner Selecta Biosciences’ licensing deal with Astel...
Redeye provides its initial take on Genovis’ Q4 2022 report, which came in substantially below our expectations on the EBIT level due to a S...
Redeye comments on Genovis following today's news regarding a sublicensing of Xork to Astellas Pharma worth up to USD139m, with USD4m upfron...
Redeye returns with an updated take on the pick-and-shovel play Genovis following a site visit and change of lead analyst.
Redeye leaves a more elaborate take on Genovis following its Q3 2022 report.
Redeye provides its initial take on Genovis’ Q3 2022 report, which came in just below our expectations on sales but significantly above our ...
Redeye returns with a follow-up note to Genovis’ Q2’22 report.
Redeye provides its initial take on Genovis’ Q2’22 report, which came in below our expectations.
Redeye endorses Genovis entering into a service agreement with evitria AG for LC-MS analysis of recombinant antibodies.
Redeye returns with a follow-up note to Genovis’ Q1’22 report.
Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in the Enzyme business.
Top Picks increases one of its largest positions even further, following solid operational development and a falling stock price.
Redeye returns with a follow-up note to Genovis’ Q4’21 report.
Redeye returns with a follow-up note to Genovis’ Q2’21 report and continues to have a positive long-term view of the case.
Redeye regards Genovis’ Q2’21 report as solid and finds it encouraging to see continued high growth in the core Analytics segment.
